The role of receptor binding in drug discovery.
Radioligand receptor binding has been used extensively to identify and characterize a host of receptors and enzymes targeting virtually every therapeutic area. Many drug discovery programs have been based on the utilization of radioligand receptor binding technology to identify lead compounds which interact with receptors likely to be important in neuronal, immunological, gastrointestinal, and cardiovascular function/dysfunction. There are several obvious advantages to using in vitro receptor binding as a first level screen when compared to in vivo pharmacometric screens. Scientifically, the structure activity data generated in binding assays is a direct reflection of the ligand/receptor interaction minus the complications which result from secondary events, bioavailability, and pharmacodynamic issues. Technically, the binding studies require only a small amount of test compound (< or = 1 mg), while whole animal studies routinely need gram quantities. Similarly, only a small amount of tissue is required, compared with the cost of purchase and maintenance of live animals for in vivo screening. Supply and labor costs are drastically reduced due to the limited volume and test tube based technology of receptor binding. For these reasons receptor binding assays have been utilized with considerable success to discover site specific lead compounds in virtually every therapeutic area.
NovaScreen, Division of Scios Nova Inc., Baltimore, Maryland 21224.
P M
PM
Sweetnam
L
L
Caldwell
J
J
Lancaster
C
C
Bauer
B
B
McMillan
W J
WJ
Kinnier
C H
CH
Price
D000818:Animals; D015195:Drug Design; D006801:Humans; D011955:Receptors, Drug / Q000378:metabolism*
D011955:Receptors, Drug